He’s strong and confident.
REGENX's NAV™ Technology is being used in research to treat MPS I, a rare genetic disease.
-
learn more... -
Fuller Golden Years.
learn more...REGENX's NAV™ Technology is being used in Alzheimer's treatment research.
-
Already thinking ahead.
learn more...REGENX's NAV™ Technology is being studied for Batten Disease, a rare inherited disorder of the nervous system that begins in childhood.
-
He’ll keep up with her.
learn more...REGENX’s NAV™ Technology is helping make blood clotting factors needed for Hemophilia patients.
-
She has a brighter future.
learn more...REGENX’s NAV™ Technology has the potential to correct progressive vision loss due to Retinitis Pigmentosa.
REGENX BioSciences is developing novel personalized
therapies based on gene delivery technology.
NAV™ Therapeutics
REGENX Biosciences has developed NAV, a gene delivery technology that includes proprietary recombinant adeno-associated viral (rAAV) vectors.
Learn about our collaboration and license programs
REGENX Biosciences Consortium awarded $7.7M Grant for Clinical Development Program using NAV rAAV8
REGENX Biosciences Receives FDA Orphan Designation for Treatment of Familial Hypercholesterolemia
REGENX and Asklepios Enter into Agreement for Treatments for Hemophilia A using NAV(TM) rAAV8
more